纾萎方治疗脾虚瘀热互结型萎缩性胃炎的临床研究

Clinical study on treating atrophic gastritis of Pixu combined Yure type with Shuwei

目的:观察纾萎方治疗脾虚瘀热互结型慢性萎缩性胃炎(CAG)的临床疗效和安全性。方法:收集门诊脾虚瘀热互结型慢性萎缩性胃炎患者86例,随机分为两组。治疗组44例予纾萎方,对照组42例予胃复春,疗程均为六个月。观察治疗前后两组临床症状和病理组织的变化情况。结果:病理综合疗效:治疗组总有效率72.73%,对照组47.62%(x2=5.4846,P=0.0194);中医症候疗效:治疗组总有效率93.18%,对照组38.10%;中医证候总积分比较,治疗组优于对照组,差异有统计学意义(P<0.01)。结论:纾萎方治疗脾虚瘀热互结型慢性萎缩性胃炎不仅明显改善临床症状,而且对CAG、IM及ATP有逆转作用。

Objective： To observe the efficacy and safety of treating CAG of Pixu combined Yure type atrophic gastritis with Shuwei decoction. Methods： 86 cases were randomly divided into two groups, the treatment group in which 44 cases were treated by Shuwei decoction for six months, and the control group in which 42 cases were treated by Weifuchun for six months. The clinical symptoms and pathological changes were observed after treatment. Results： The total effective rate of clinical pathology in the treatment group was 72.73%, and in the control group was 47.62% （x2=5.4846, P-0.0194）. The total effective rate of symptom efficacy in the treated group was 93.18%, the control group was 38.10%. The total syndrome scores in the treatment group had better effect than in the control group （P〈0.01）. Conclusion： The Shuwei decoction on treating patients with CAG has better efficacy than Weifuchun not only significantly improved the clinical symptoms, but also had the role which could reverse CAG, IM and ATP.